SGX will be responsible for completing the preclinical development of the leading drug candidate. Additionally, it will be required to submit an investigational new drug application to the Food and Drug Administration. SGX will also have to complete an initial phase I clinical study. After that, Novartis will conduct the added clinical development and commercialization of the compound.
Novartis trades by way of an American depositary share in the U.S. Lately, the ADRs were up 57 cents, or 1%, to $55.83.- Loading Comments...
- Loading Comments...
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,231.70 | 1,091.13 | 2,157.15 | 34.89 |
Oil *
76.09
|
|
DOWN
59.56
|
DOWN
7.38
|
DOWN
9.75
|
UP
0.15
|
10 Yr
3.49%
SPDR Gold
108.51
|
|
-0.58%
|
-0.67%
|
-0.45%
|
+0.43%
|
Data delayed 20 minutes |
